Literature DB >> 25657994

The Potential Role of BRCA1-Associated ATM Activator-1 (BRAT1) in Regulation of mTOR.

Eui Young So1, Toru Ouchi1.   

Abstract

BRCA1-associated ATM activator-1 (BRAT1) was identified by our group as a DNA damage response (DDR) protein, which can bind with many DDR proteins and regulates their functions after DNA damage. However, previous study has also implicated BRAT1 as a regulator of cell growth and apoptosis. In this study, targeted gene deletion showed that BRAT1 is critical in stability and serum-induced expression of mTOR and downstream protein. Conditional deletion of BRAT1 of mouse embryonic fibroblasts suppressed serum-induced cell cycling progress. Our results suggest that BRAT1 is essential factor for PIKK signaling cascades.

Entities:  

Keywords:  BRCA1; Cell cycle; Cell signaling; Human cervical carcinoma

Year:  2013        PMID: 25657994      PMCID: PMC4314932     

Source DB:  PubMed          Journal:  J Cancer Biol Res        ISSN: 2373-9436


  9 in total

1.  Regulation of ATM/DNA-PKcs Phosphorylation by BRCA1-Associated BAAT1.

Authors:  Mutsuko Ouchi; Toru Ouchi
Journal:  Genes Cancer       Date:  2010-12

2.  Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK catalytic subunit.

Authors:  Eui Young So; Toru Ouchi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

3.  ATM activation by ionizing radiation requires BRCA1-associated BAAT1.

Authors:  Jason A Aglipay; Sarah A Martin; Hideyuki Tawara; Sam W Lee; Toru Ouchi
Journal:  J Biol Chem       Date:  2006-02-01       Impact factor: 5.157

4.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

5.  Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias.

Authors:  Jane Starczynski; William Simmons; Joanne R Flavell; Phillip J Byrd; Grant S Stewart; Harjit S Kullar; Alix Groom; John Crocker; Paul A H Moss; Gary M Reynolds; Meri Glavina-Durdov; A Malcolm R Taylor; Christopher Fegan; Tatjana Stankovic; Paul G Murray
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression.

Authors:  L Carlessi; L De Filippis; D Lecis; A Vescovi; D Delia
Journal:  Cell Death Differ       Date:  2009-02-20       Impact factor: 15.828

7.  mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex.

Authors:  John T Cunningham; Joseph T Rodgers; Daniel H Arlow; Francisca Vazquez; Vamsi K Mootha; Pere Puigserver
Journal:  Nature       Date:  2007-11-29       Impact factor: 49.962

Review 8.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

9.  Phosphorylation of SMC1 by ATR is required for desferrioxamine (DFO)-induced apoptosis.

Authors:  E Y So; M Ausman; T Saeki; T Ouchi
Journal:  Cell Death Dis       Date:  2011-03-10       Impact factor: 8.469

  9 in total
  3 in total

1.  BRAT1 links Integrator and defective RNA processing with neurodegeneration.

Authors:  Zuzana Cihlarova; Jan Kubovciak; Margarita Sobol; Katerina Krejcikova; Jana Sachova; Michal Kolar; David Stanek; Cyril Barinka; Grace Yoon; Keith W Caldecott; Hana Hanzlikova
Journal:  Nat Commun       Date:  2022-08-26       Impact factor: 17.694

2.  BRAT1 deficiency causes increased glucose metabolism and mitochondrial malfunction.

Authors:  Eui Young So; Toru Ouchi
Journal:  BMC Cancer       Date:  2014-07-29       Impact factor: 4.430

3.  Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer.

Authors:  Shiwanthi L Ranasinghe; Glen M Boyle; Katja Fischer; Jeremy Potriquet; Jason P Mulvenna; Donald P McManus
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.